• Corpus ID: 6271375

Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.

  title={Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.},
  author={Risa Imai and Makoto Morimoto and H Marumo and T Kobayashi and Takashi Tsuruo and Makoto Inaba and Shigeru. Tsukagoshi and Yoshio Sakurai},
  volume={72 6},
The antitumor activity of 7-N-(p-hydroxyphenyl)-mitomycin C (M-83) was compared with that of mitomycin C (MMC) in rodent tumor systems. M-83 exhibited more potent activity than MMC against the ascitic form of lymphocytic leukemia P388 and fibrosarcoma Meth 1, and doses of over 5 mg/kg of M-83 (1/6 LD50) resulted in some 60-day survivors. The chemotherapeutic ratio (optimal dose/MED) of M-83 was around 64 and was estimated to be approximately 5 to 8 times higher than that of MMC. Upon… 
Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C.
M-83 was markedly effective against solid tumors of sarcoma 180, Meth 1, Meth A and Lewis lung carcinoma, by a single intravenous injection and inhibited more strongly the incorporation of the radioactive precursor into DNA than that into RNA or protein at the concentration of 3 X 10(-3) mM.
In the tumor, the peak concentration and AUC600 detected by radioassay correlated well with the value of drug efficacy TRW/CRW, which was thought to be affected by inactivation of the agent in the tumor.
Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice.
  • F. Asanuma
  • Medicine, Chemistry
    The Journal of antibiotics
  • 1985
In the tumor, the peak concentration and AUC60(0) detected by radioassay correlated well with the value of drug efficacy TRW/CRW, which was thought to be affected by inactivation of the agent in the tumor.
The action of 7-N-(p-hydroxyphenyl)mitomycin C [M-83] in suppressing murine immune response.
The immuno-suppressive activities of M-83, a derivative of mitomycin C, which has better antitumor activity against murine tumors, was investigated in mice and resulted in an apparent but relatively transient reduction in both plaque-forming cell production and delayed type hypersensitivity reaction to sheep red blood cells.
Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay
The results indicate that KW 2083 might be more useful than mitomycin C in clinical practice, and the clonogenic assay system might prove to be a very effective tool for an in vitro phase II study of new drugs.
Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C
The Phase I study of N-7-(p-hydroxyphenyl)-mitomycin C indicates that the recommended starting dose for Phase II studies for patients without significant myelosuppression would be 50 mg/m2 at 6 week intervals in an intravenous push.
[Studies on the physiological disposition and pharmacokinetics of 7-N-(p-hydroxyphenyl)-mitomycin C].
The total clearance of KW 2083 was higher than mitomycin C and hence the biological half life of Kw 2083was shorter, which may suggest less toxicity of K W 2083 to the host cells.
Development and Application of a Sensitive Enzyme Immunoassay for 7-A /-( p-Hydroxyphenyl ) mitomycin C 1
An antibody specific for 7-A/-<p-hydroxyphenyl)mitomycin C (M83) was developed and used in a simple and sensitive enzyme immunoassay for detection of this anticancer drug in serum. The imino group of
Specificity and use of antisera produced against anticancer drugs.
The importance of drug monitoring has become increasingly evident for achieving optimum therapeutic effectiveness and minimizing side effects because the response to therapy is often better correlated with the concentration of the drug in the fluid than with prescribed dosage, and the pharmacokinetics varies, depending largely upon the individual circumstances and the clinical state of the patients.
Phage inactivation and DNA strand scission activities of 7-N-(p-hydroxyphenyl)mitomycin C.
A new derivative of mitomycin C (MMC), 7-N-(p-hydroxyphenyl)mitomycin C (M-83), had higher phage inactivation activity against phages phiX174 and PM2 than MMC, and also higher DNA strand scission